2020
Research article *1
Individualised prognosis in dementia research
Authors include Ioannis Tarnanas and Panagiotis Vlamos.
THERAPY RESPONSE PREDICTION
Building the therapy response prediction platform.
Healing, made predictable.
Working models and published biomarker research are our starting point. We are building a proprietary platform for therapy-specific response prediction.
One platform. Therapy-specific models. Individual response profiles.
THE QUESTION
Will this treatment help this person?
This is the question at the centre of NUMEN. Our ambition is to make individual response a stronger part of treatment development and, ultimately, help reduce avoidable treatment attempts.
Know more before treatment begins.
THE PLATFORM
One machine. Many scores.
We are building a common technology foundation for different treatment questions. Therapy-specific models are its applications. Individual response profiles make their outputs understandable.
The platform
Proprietary technology to develop, evaluate and deliver response models.
The models
Defined applications for a specific therapy, population and outcome.
The profiles
Response estimates, confidence and context in one view.
We are not building a score. We are building the machine that builds them.
THE PLATFORM OUTPUT
One person. One therapy. A clearer view.
The response profile brings the model’s estimate and the information needed to interpret it together. The goal is an answer a research team can examine and use.
In development
Individual response profile
- Expected response
- An estimate for a defined therapy and treatment outcome.
- Confidence in the estimate
- Uncertainty and the strength of supporting evidence.
- Treatment context
- The population, time horizon and model behind the estimate.
Individual response profile · In development · Illustrative interface
WHO WE BUILD FOR
For teams developing the next therapies.
Built for translational medicine and clinical development teams investigating individual treatment response. We focus on questions that matter to the next research or development decision.
OUR FIRST APPLICATION
Psychedelic therapies. Our first focus.
Our first study and initial response-score development focus on psychedelic therapies.
A focused beginning. A broader platform.
OUR STARTING POINT
Working models. Published research.
NUMEN brings existing modelling capability together with a team whose work spans digital biomarkers and individual prognosis. *1 *2 Our platform development builds on that foundation.
Read publication
2026
Perspective *2
Digital Neuro Fingerprints
Authors include Ioannis Tarnanas, Martin Wyss and Panagiotis Vlamos.
THE PEOPLE
Technology builders. Biomarker researchers.
Technical depth, scientific leadership and company-building expertise, focused on individual treatment response.
Martin Wyss
Founder & CEO
Meet MartinIoannis Tarnanas
Chief Scientific Officer
Meet IoannisPanagiotis Vlamos
Scientific Advisor
Meet PanagiotisTHE LONG-TERM AMBITION
Beyond one score. Understanding response over time.
Our long-term ambition is to build individualised models that reveal more about how response changes over time and help shape better-informed future decisions.
The individual remains more than the model.
WORK WITH NUMEN
Build the next stage with NUMEN.
Bring a research question, a complementary capability or a shared ambition for the company we are building.